Inceptionr LLC Makes New Investment in Cytokinetics, Incorporated $CYTK

Inceptionr LLC acquired a new position in Cytokinetics, Incorporated (NASDAQ:CYTK) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 15,974 shares of the biopharmaceutical company’s stock, valued at approximately $1,053,000.

Other institutional investors have also recently modified their holdings of the company. Monashee Investment Management LLC raised its holdings in shares of Cytokinetics by 33.3% during the 1st quarter. Monashee Investment Management LLC now owns 100,000 shares of the biopharmaceutical company’s stock valued at $6,591,000 after buying an additional 25,000 shares in the last quarter. First Trust Advisors LP boosted its stake in Cytokinetics by 14.4% in the first quarter. First Trust Advisors LP now owns 145,890 shares of the biopharmaceutical company’s stock worth $9,616,000 after buying an additional 18,366 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Cytokinetics by 75.2% in the first quarter. Dimensional Fund Advisors LP now owns 94,503 shares of the biopharmaceutical company’s stock worth $6,229,000 after buying an additional 40,574 shares in the last quarter. AlphaCentric Advisors LLC grew its position in Cytokinetics by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the biopharmaceutical company’s stock valued at $370,000 after acquiring an additional 305 shares during the last quarter. Finally, Swiss National Bank grew its position in Cytokinetics by 2.5% during the first quarter. Swiss National Bank now owns 229,800 shares of the biopharmaceutical company’s stock valued at $15,146,000 after acquiring an additional 5,600 shares during the last quarter.

Insider Activity at Cytokinetics

In other Cytokinetics news, EVP Andrew Callos sold 15,000 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $85.80, for a total transaction of $1,287,000.00. Following the completion of the sale, the executive vice president owned 58,555 shares of the company’s stock, valued at $5,024,019. This represents a 20.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the firm’s stock in a transaction on Monday, July 13th. The stock was sold at an average price of $82.02, for a total transaction of $615,150.00. Following the completion of the sale, the chief executive officer directly owned 377,820 shares in the company, valued at approximately $30,988,796.40. This trade represents a 1.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 132,036 shares of company stock worth $9,816,694 over the last ninety days. Insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Stifel Nicolaus lifted their price target on shares of Cytokinetics from $98.00 to $108.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. UBS Group raised shares of Cytokinetics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $69.00 to $115.00 in a research note on Monday, June 29th. HC Wainwright increased their target price on shares of Cytokinetics from $136.00 to $140.00 and gave the company a “buy” rating in a report on Monday, May 11th. Truist Financial set a $106.00 target price on shares of Cytokinetics in a research report on Tuesday, May 5th. Finally, Barclays boosted their price target on shares of Cytokinetics from $87.00 to $95.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $99.90.

Cytokinetics Stock Performance

Shares of CYTK stock opened at $80.74 on Friday. Cytokinetics, Incorporated has a fifty-two week low of $32.89 and a fifty-two week high of $88.31. The stock has a 50 day moving average price of $78.54 and a two-hundred day moving average price of $69.83. The company has a market capitalization of $10.05 billion, a P/E ratio of -11.80 and a beta of 0.42.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.67). The company had revenue of $19.36 million for the quarter, compared to analysts’ expectations of $8.52 million. During the same period last year, the company posted ($1.36) EPS. The business’s revenue for the quarter was up 1112.5% compared to the same quarter last year. As a group, equities analysts predict that Cytokinetics, Incorporated will post -6.2 earnings per share for the current year.

Cytokinetics Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.